SCHEMBL20565701

SCHEMBL20565701

Cc1ccc(CC(=O)O)c(Cl)n1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SRC P12931 1/20 0.41
EGFR P00533 3/20 0.40
ALOX15 P16050 1/20 0.40
DGAT1 O75907 1/20 0.40
PTGDR2 Q9Y5Y4 5/20 0.39
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
HTT P42858 1/20 0.39
CYP19A1 P11511 1/20 0.39
AKR1B1 P15121 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
PTGS2 P35354 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30034504 1.00 ALDH1A1 (0.42) ALDH1A1MAPK1SMN1; SMN2SRCEGFR
SCHEMBL940930 0.81 AKR1B1 (0.41) ALDH1A1SRCDGAT1KDM4EAKR1B1
SCHEMBL9181886 0.78 CTRC (0.38) ALDH1A1MAPK1SMN1; SMN2EGFRKDM4E
SCHEMBL22983470 0.78 AKR1B1 (0.38) ALDH1A1PTGDR2KDM4EAKR1B1TDP1
SCHEMBL6224336 0.78 CYP19A1 (0.46) ALDH1A1SRCALOX15PTGDR2KDM4E
SCHEMBL30564474 0.78 SRC (0.41) ALDH1A1SRCALOX15PTGDR2KDM4E
SCHEMBL29862772 0.78 AKR1B1 (0.38) ALDH1A1PTGDR2KDM4EAKR1B1TDP1
SCHEMBL30034021 0.77 POLB (0.44) ALDH1A1PTGDR2KDM4ETDP1
SCHEMBL20565255 0.77 POLB (0.44) ALDH1A1PTGDR2KDM4ETDP1
SCHEMBL20565266 0.77 MTNR1A (0.41) ALDH1A1MAPK1SMN1; SMN2EGFRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250387379-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS NFLECTION THERAPEUTICS INC (US) 2025-12-25 US disclosed
EP-4233834-A2 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS NFlection Therapeutics, Inc. (US) 2023-08-30 EP disclosed
EP-4233834-A2 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS NFlection Therapeutics, Inc. (US) 2023-08-30 EP disclosed
EP-4233865-A2 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS NFlection Therapeutics, Inc. (US) 2023-08-30 EP disclosed
EP-4233865-A2 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS NFlection Therapeutics, Inc. (US) 2023-08-30 EP disclosed
US-20230013227-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS NFLECTION THERAPEUTICS, INC. 2023-01-19 US disclosed
US-20230013227-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS NFLECTION THERAPEUTICS, INC. 2023-01-19 US disclosed
US-11542271-B2 Fused heteroaromatic-aniline compounds for treatment of dermal disorders NFLECTION THERAPEUTICS, INC. (US) 2023-01-03 US disclosed
US-11542271-B2 Fused heteroaromatic-aniline compounds for treatment of dermal disorders NFLECTION THERAPEUTICS, INC. (US) 2023-01-03 US disclosed
CN-111093658-B Fused heteroaromatic-aniline compounds for the treatment of skin diseases 恩福莱克逊治疗有限公司 2022-10-14 CN disclosed
CN-113645964-A Arylaniline and heteroarylaniline compounds for use in fetal marker therapy 恩福莱克逊治疗有限公司 2021-11-12 CN disclosed
EP-3883554-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS NFlection Therapeutics, Inc. (US) 2021-09-29 EP disclosed
EP-3883553-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS NFlection Therapeutics, Inc. (US) 2021-09-29 EP disclosed
US-10988483-B2 Fused heteroaromatic-aniline compounds for treatment of dermal disorders NFLECTION THERAPEUTICS, INC. (MA) 2021-04-27 US disclosed
US-10988483-B2 Fused heteroaromatic-aniline compounds for treatment of dermal disorders NFLECTION THERAPEUTICS, INC. (MA) 2021-04-27 US disclosed
US-20200172550-A1 FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS NFLECTION THERAPEUTICS, INC. 2020-06-04 US disclosed
US-20200172550-A1 FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS NFLECTION THERAPEUTICS, INC. 2020-06-04 US disclosed
CN-111093658-A Fused heteroaromatic-aniline compounds for the treatment of skin diseases 恩福莱克逊治疗有限公司 2020-05-01 CN disclosed
EP-3624795-A1 FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS NFlection Therapeutics, Inc. (US) 2020-03-25 EP disclosed
WO-2018213807-A1 FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS NFLECTION THERAPEUTICS, INC. (US) 2018-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230013227-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS HTR3C, NDUFA13, NDUFAF3 ALDH1A1 1050/4885MAPK1 3895/4885SMN1; SMN2 2306/4885
US-10988483-B2 Fused heteroaromatic-aniline compounds for treatment of dermal disorders TYR, CYP19A1, BRAF ALDH1A1 724/4885MAPK1 141/4885SMN1; SMN2 3250/4885
US-20200172550-A1 FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS TYR, CYP19A1, BRAF ALDH1A1 724/4885MAPK1 141/4885SMN1; SMN2 3250/4885
US-11542271-B2 Fused heteroaromatic-aniline compounds for treatment of dermal disorders TYR, CYP19A1, BRAF ALDH1A1 705/4885MAPK1 137/4885SMN1; SMN2 3256/4885
US-20250387379-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS SUB1, AHR, NCOA3 ALDH1A1 479/4885MAPK1 1687/4885SMN1; SMN2 4137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.